Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions.

Revati VarmaJeffrey P StaabEric T MateyJessica A WrightBrototo DebKonstantinos N LazaridisLawrence A SzarkaKent R BaileyAdil E Bharucha

Published in: Neurogastroenterology and motility (2023)

The homozygous SLC6A4 long/long genotype confers better symptom resolution for patients with disorders of gut-brain interaction who take selective serotonin reuptake inhibitors than do the homozygous short/short or heterozygous long/short genotypes.

Keyphrases

white matter
resting state
early onset
cerebral ischemia
high intensity
genome wide
emergency department
single molecule
gene expression
multiple sclerosis
dna methylation
transcription factor
adverse drug